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Allosteric bindingLipoxygenases (LOXs) and cyclooxygenases (COXs) metabolize poly-unsaturated fatty acids into inﬂam-
matory signaling molecules. Modulation of the activity of these enzymes may provide new approaches
for therapy of inﬂammatory diseases. In this study, we screened novel anacardic acid derivatives as mod-
ulators of human 5-LOX and COX-2 activity. Interestingly, a novel salicylate derivative 23a was identiﬁed
as a surprisingly potent activator of human 5-LOX. This compound showed both non-competitive activa-
tion towards the human 5-LOX activator adenosine triphosphate (ATP) and non-essential mixed type
activation against the substrate linoleic acid, while having no effect on the conversion of the substrate
arachidonic acid. The kinetic analysis demonstrated a non-essential activation of the linoleic acid conver-
sion with a KA of 8.65 lM, aKA of 0.38 lM and a b value of 1.76. It is also of interest that a comparable
derivative 23d showed a mixed type inhibition for linoleic acid conversion. These observations indicate
the presence of an allosteric binding site in human 5-LOX distinct from the ATP binding site. The activa-
tory and inhibitory behavior of 23a and 23d on the conversion of linoleic compared to arachidonic acid
are rationalized by docking studies, which suggest that the activator 23a stabilizes linoleic acid binding,
whereas the larger inhibitor 23d blocks the enzyme active site.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
The lipoxygenases (LOXs) and the cyclooxygenases (COXs) are
enzymes that play key roles in the major metabolic pathways of
poly-unsaturated fatty acids (PUFAs). These pathways convert PU-
FAs into inﬂammatory mediators such as lipoxins, leukotrienes,
and prostaglandins, which play a regulatory role in numerous
inﬂammatory and proliferative diseases including asthma, arthritis
and cancer.1 The biological roles of LOXs and COXs in metabolic
pathways towards inﬂammatory mediators and signaling mole-
cules demonstrate the utility of these enzymes as therapeutic
targets.
Lipoxygenases are non-heme iron containing enzymes. There
are four types of lipoxygenases with different positional speciﬁci-
ties for arachidonic acid oxidation present in mammalian tissues;
5-LOX, 8-LOX, 12-LOX and 15-LOX. In general, lipoxygenases com-
prise of two domains in which the N-terminal domain is the regu-latory domain and the C-terminal domain is the catalytic domain.2
Although, human lipoxygenases show about 60% sequence similar-
ities,3 their regulatory mechanisms are variable. Unlike other LOXs,
5-LOX activity requires the presence of activators such as Ca2+ and
adenosine triphosphate (ATP). In addition, different types of LOXs
have been identiﬁed based on their distribution over different tis-
sues. For example, 12-LOX is subdivided in platelet 12-LOX (p12-
LOX) and 12R-LOX. As its name implies, platelet 12-LOX (p12-
LOX) is mostly found in platelets, whereas 12R-LOX is most fre-
quently found in skin cells.4,5 Similarly, 15-LOX is subdivided in
15-LOX-1 and 15-LOX-2. 15-LOX-1 is highly expressed in leuko-
cytes and airways endothelial cells,6,7 whereas 15-LOX-2 is ex-
pressed in multiple tissues such as prostate, lung, cornea, liver,
colon, kidney, and brain but not in leukocytes.8 Moreover, stimula-
tion of cells by interleukin (IL)-4 and IL-13 shows selective
enhancement of the 15-LOX-1 expression and not 15-LOX-2
expression.9 In addition, 15-LOX-1 and 15-LOX-2 lack similarity
at the primary sequence level, which also hints at distinct biologi-
cal roles and the possibility to develop selective inhibitors or
activators.10
The overexpression of certain lipoxygenases has been reported
in numerous inﬂammatory diseases. For example, increased 15-
LOX-1 expression in bronchial epithelium, which is accompanied
by elevated concentrations of 15-hydroxyeicosatetraenoic acid
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bronchitis.11,12 In addition, activity of other LOXs isoenzymes has
been reported to be signiﬁcantly increased in disease conditions.
For example, upregulation of 12R-LOX activity has been observed
in the development of skin tumor and melanoma.13,14 In addition,
overexpression of 5-LOX has been reported to contribute to airway
inﬂammation in asthma and to the growth of some tumors in, for
example, lung, prostate, brain and colon.15–19 In contrast, lipoxins,
another type of arachidonic acid metabolites, have been reported
to have important roles as anti-inﬂammatory and pro-resolution
mediators,20 which play an important role in the termination of
immune responses. Production of lipoxins upon inﬂammatory
stimulation involves two main lipoxygenase-mediated pathways.
The ﬁrst pathway involving 15-LOX and 5-LOX occurs in mucosal
tissues, such as the respiratory tract, gastrointestinal tract and
the oral cavity. The second pathway involves 5-LOX and p12-
LOX, in which 5-LOX produces the Leukotriene A4 (LTA4) and
p12-LOX converts the LTA4 to lipoxin A4 (LXA4).21 Lipoxin A4
has important roles in stopping neutrophil migration, stimulation
of monocyte and macrophage activation, and inhibition of leukotri-
ene B4 formation.20 Induction of 15-LOX-1 by IL-13 in synovial tis-
sues of patients with rheumatoid arthritis enhances the level of
LX4 in a negative feedback loop to limit inﬂammatory responses
induced by pro-inﬂammatory mediators such as Leukotriene
B4.22 Another study showed that prior to induction with peroxi-
some proliferator-activated receptors gamma (PPARc) agonists in
brain, the 5-LOX expression was enhanced in association with
the increase of cerebral LX4 production and inhibition of Leukotri-
ene B4 production.23 The association of 5-lipoxygenase activity in
the production of both pro- and anti-inﬂammatory mediators indi-
cates its crucial role in pathophysiological processes of inﬂamma-
tion. Based on these ﬁndings we speculate that activators of 5-
lipoxygenase might also have beneﬁcial effects in inﬂammation
by triggering the termination of immune responses. In addition,
it might be speculated that the redirection of lipoxygenase metab-
olism by 5-LOX activators towards other substrates might also lead
to the formation of less harmful pro-inﬂammatory products. En-
zyme activation as a concept in drug discovery has been shown
to be successful for glucokinase activators.24 We stress, however,
that lipoxygenase activation by small molecules with the aim to
limit inﬂammation is a novel concept and lacks experimental
proof.
Prostaglandin endoperoxide H synthases (PGHSs), are also
known as cyclooxygenases (COXs), catalyze the formation of pros-
taglandins (PGs). COXs are comprised of two main sites, a heme
site with peroxidase activity and a bis-oxygenase site. COXs con-
vert arachidonic acid into prostaglandin endoperoxide H2 (PGH2)
in a two steps process. The ﬁrst step is enzymatic catalysis of the
insertion of two molecules O2 into arachidonic acid to generate
prostaglandin G2 (PGG2). The second step is the peroxidase reac-
tion in which the PGG2 is oxidized to PGH2 by a two electron
abstraction. The peroxidase reaction occurs at a heme-containing
active site located near the protein surface, whereas the oxygena-
tion reaction occurs in a hydrophobic channel in the core of the
enzyme.25 The COX isoenzymes COX-1 and COX-2 are differentially
expressed in various tissues. Under normal conditions, COX-1 is
expressed in most mammalian cells, whereas COX-2 is not ex-
pressed. The COX-2 expression is increased under inﬂammatory
conditions. Animal models of inﬂammatory arthritis indicate that
overexpression of COX-2 is responsible for the increase of PGs in
joint tissue and cause acute and chronic inﬂammation.26 Elevated
levels of PGs were observed in inﬂammatory bowel diseases
(IBD).27,28 A similar behavior was observed in cancers. For example,
the expression of COX-2, but not COX-1, was observed in various
regions of the colon in human colorectal cancer.29,30 Therefore,COX-2 inhibition is considered to be a relevant therapeutic strat-
egy for treatment of cancer and inﬂammatory diseases.
Anacardic acid is a naturally occurring 6-alkyl substituted salic-
ylate that is identiﬁed from cashew nutshells. Previously, we found
that this salicylate and its derivatives are allosteric regulators of
lipoxygenase activity. We identiﬁed an allosteric inhibitor of soy-
bean lipoxygenase-1 (SLO-1) (19) and an allosteric activator of po-
tato 5-lipoxygenase (5-LOXs) (21).31 It should, however, be noted
that the lack of similarity between the human and plant enzymes
prohibits extrapolation or these data towards biological effects in
cell-based studies.32 Therefore, we continue our previous studies
by exploring the inhibitory potency of a salicylate-based com-
pound collection for inhibition of human 5-lipoxygenase and
cyclooxygenase-2. In this study, we describe the synthesis of a no-
vel focused collection of salicylate-based compounds and we
investigate their inﬂuence on the enzyme activity of human 5-
LOX and human COX-2. This enabled the identiﬁcation of a novel
activator 23a and a mixed inhibitor 23d of the conversion of the
linoleic acid by h-5-LOX. Interestingly, no effect on the arachidonic
acid conversion was observed. Enzyme kinetic investigations dem-
onstrated that activator 23a binds to an allosteric binding site on
h-5-LOX that is different from the ATP regulatory site. Modeling
studies suggest that 23a binds close to the substrate linoleic acid,
thereby enhancing the Km and kcat for its conversion.
2. Results and discussion
2.1. Synthesis
Our salicylate-based compound collection that is inspired by
anacardic acid (14) comprises of the previously published salicy-
lates 14–19, and 21 and the newly synthesized salicylates 20, 22,
23a–d, 24b–c and benzoxazole 25. The synthesis of anacardic acid
(14) and its derivatives 15–19, and 21 were described previously
by Ghizzoni et al.33,34 This collection includes the previously de-
scribed compounds that were reported as inhibitors or activator
of soybean lipoxygenase-1 (SLO1) (19) and potato 5-LOX (21).31
The newly synthesized compounds were inspired by compound
19 and 21, which contain either a 6-phenylethyl substitution or a
6-alkoxy substitution. This was merged into a para-alkoxybenzyl-
oxy substitution, which can be synthesized using convenient
methods.
The starting materials, acetonide 1 (Scheme 1) and triﬂate 10
(Scheme 2), were synthesized as described by Uchiyama et al.35
2-Hydroxy-6-(nonyloxy)benzoic acid (22) was synthesized from
commercially available 1-bromononane and acetonide 1 following
synthetic procedure described by Ghizzoni et al.33 (Scheme 1). p-
Alkyloxybenzylbromides (3a–d) and m-alkyloxybenzylbromides
(5b–c) were prepared in three steps from p-hydroxybenzaldehyde
or m-hydroxybenzaldehyde. The ﬁrst step involves the coupling of
alkylbromides with the hydroxybenzaldehydes to give the corre-
sponding ethers. Subsequently, the benzaldehydes were reduced
to the corresponding benzyl alcohols 2a–d and 4b–c36 in high
yields. Direct coupling of benzyl alcohols to phenol 1 by Mitsunobu
reaction did not provide the desired ethers. Therefore, the ben-
zylalcohols 2a–d and 4b–c were brominated using PBr3 to give
the corresponding benzylbromides 3a–d and 4b–c. The benzylbro-
mides were coupled to acetonide 1 to give the corresponding prod-
ucts 12a–d and 13b-c in high yields (>70%). Subsequently, the
acetonide protecting group was cleaved using potassium hydrox-
ide in THF to provide the ﬁnal products 23a–d as potassium salts
(Scheme 1). Isolation of salicylates 23a–d as salicylate salts proved
to be necessary to avoid degradation of the p-alkoxybenzylethers
by the strongly acidic salicylic acids. Acidiﬁcation results a slow
hydrolysis of the product to give 2,6-dihydroxybenzoate and the
Scheme 1. Reagents and conditions: (a) SOCl2, DMAP, DME, acetone, 0 C for 1 h, then rt overnight; (b) 1-bromo alkane, K2CO3, DMF, rt overnight; (c) NaBH4, MeOH, 0 C for
1 h, then rt for 30 min; (d) PBr3, CH2Cl2, 0 C for 1.5 h; (e) 1-bromononane, K2CO3, DMF, rt overnight; (f) compound 1, K2CO3, DMF, rt overnight; (g) 5 M KOH, THF, 60 C
overnight.
Scheme 2. Reagents and conditions: (a) decanoylchloride, AlCl3, CH2Cl2, 60 C for 1 h; (b) NH2NH2H2O, KOH, 1-octanol, reﬂux, 3 h; (c) trimethylsilyl-acetylene, CuI,
PdCl2(PPh3)2, Et2NH, PPh3, CH3CN, (MW, 120 C, 95 W, 35 min); (d) TBAF, THF, 0 C, 10 min; (e) CuI, PdCl2(PPh3)2, Et2NH, triﬂate 10, CH3CN (MW, 120 C, 70 W, 35 min); (f) H2,
Pd/C, MeOH, 45 C, 24 h; (g) 2-aminophenol, polyphosphatic acid, 180 C for 6.5 h.
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by the electrondonating alkyloxy substituent on the para- postion.
As expected, for the meta-substituted benzyl substituents 24b–c
this problem was not observed.
p-Decylphenyl bromide (8) (Scheme 2) was prepared from bro-
mobenzene 6 and decanoylchloride following two reaction steps.
The ﬁrst step was the formation of 1-(4-bromophenyl)decan-1-
one 7 through Friedel–Craft acylation using AlCl3.37 The second
step was the Wolff–Kishner reduction of 1-(4-bromophenyl)dec-
an-1-one 7 using hydrazine monohydrate and potassium hydrox-
ide to give product 8.37 Subsequently, arylbromide 8 was
converted to alkyne 9 by coupling with trimethyl-silyl (TMS) acet-
ylene by a Sonogashira reaction and subsequent removal of the
TMS protection using tetra butyl ammonium ﬂuoride (TBAF). The
resulting alkyne 9 was coupled to triﬂate 1038 to give the product
in high yield (80%), which was subsequently converted into prod-
uct 20 by catalytic hydrogenation.
2.2. Enzyme inhibition
LOXs are non-heme iron dependent enzymes. Benzoxazole 25
was designed based on the presumption that iron-binding is a
key property for the inhibition of lipoxygenases and cyclooxygen-ases. Benzoxazole 25 was synthesized from salicylic acid and 2-
amino phenol through direct cyclization using polyphosphoric acid
(Scheme 2).39 Compound 25 did not inhibit h-5-LOX, however it
gives 50% COX-2 inhibition at 50 lM inhibitor concentration. This
indicates that 25 is a potential starting point for development of
selective inhibitors of COX-2 (Fig. 1).
The inﬂuence of the salicylates (Table 1) on the enzyme activity
of human 5-lipoxygenase and/or cyclooxygenase-2 was investi-
gated. The h-5-LOX activity was monitored in real time by detec-
tion of the formation of the UV absorbance of the conjugated
diene 13-hydroperoxy-cis-9-trans-11-octa decanoic acid (13-
HPOD) from linoleic acid.40,41 The residual h-5-LOX activity was
monitored after 10 min pre-incubation with 50 lM of the com-
pound of interest. The COX-2 activity was determined by measur-
ing the conversion or arachidonic acid, which conversion is
monitored by the oxidation of N,N,N0,N0-tetramethyl-p-phenylene-
diamine (TMPD).42 The residual enzyme activity was measured
after 5 min pre-incubation in the presence of 50 lM of the com-
pound of interest. The enzyme activity without inhibitor present
was taken as control and set to 100% and the activity without en-
zyme present was set to 0%. The residual enzyme activities of h-5-
LOX and COX-2 in the presence of different salicylates are shown in
Figure 1.
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Figure 1. Residual enzyme activity that was observed for the screening of a salicylate-based compound collection for inhibition of h-5-LOX and COX-2 activity in the presence
of 50 lM of the respective compounds. The h-5-LOX activity was determined in presence of 100 lM linoleic acid as a substrate. The COX-2 activity was determined in
presence of 2 mM arachidonic acid as a substrate. The results presented were the average of three independent experiments and the standard deviations are shown.
Table 1
Focused compound collection
Compounds R1 R2 R3
O
R1
OOH
R2 R3
14 H H
15 H H
16 H H
17 H OH
18 H H
19 H OH
20 H OH
21 H H O
22 H H O
23a (PK131) K H
O
O
23b K H
O
O
23c K H
O
O
23d (PK147) K H
O
O
24b H H O
O
24c H H O
O
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O
HO
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of both h-5-LOX and COX-2 at 50 lM. In comparison to anacardic
acid 14, a slight improvement in the inhibitory potency of h-5-
LOX was observed for compound 17. Importantly, neither inhibi-
tion nor activation was observed from compound 21, which in
our previous report31 shows a strong activation on potato 5-LOX,
which demonstrates the difference between plant and human
enzymes.Compounds 23a–d with alkoxy substituents in the para-posi-
tions of the benzylethers, show an interesting structure activity
relationship for modulation of h-5-LOX activity. Compound 23a
shows strong activation of h-5-LOX at 50 lM, whereas compound
23b and 23cwith a longer side chain show no or little inhibition of
h-5-LOX. Furthermore, compound 23d with a branched side chain
provides almost 50% inhibitions of h-5-LOX at the same concentra-
tion. The compound is racemic at its asymmetric carbon.
Figure 2. Surface tensions of (A) anacardic acid 14 and (B) compound 23a (C) compound 23d against the logarithm of concentration. CMC values (A–C) were measured in
human 5-LOX assay conditions, Tris buffer (50 mM), 2 mM EDTA and 2 mM CaCl2, pH 7.5, rt (t = 19 C).
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Figure 3. Concentration dependent activation of the linoleic acid conversion by h-
5-LOX in the presence of various concentrations of compound 23a and in its
absence (control). The results were the average of three independent experiments
with error bars (±SD).
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pounds do not inhibit COX-2 activity more than 50% at 50 lM,
which indicates that this type of compounds has a tendency for
selective modulation of h-5-LOX compared to COX-2. Interestingly,
benzoxazole 25 inhibits the COX-2 activity by about 50%, whereas
no inhibition was observed on h-5-LOX, which indicates that fur-
ther optimization of this class of compound may be feasible.
In order to assure that the assays are performed in homogenous
solutions the critical micelle concentrations (CMCs) of the different
compounds were determined and the assays were performed at
concentration below the CMC. Homogenous solutions are required
for proper analysis of the enzyme kinetics. The CMCs for 23a and
23d at the assay conditions (50 mM Tris buffer, 2 mM EDTA and
2 mM CaCl2, pH 7.5, rt) are, respectively, 628 lM and 395 lM
(Fig. 2B and C) which indicate that micelle formation does not oc-
cur at concentrations employed for inhibition or activation of h-5-
LOX. In addition, we found a CMC value for linoleic acid of 185 lM
(Fig. 2A),43 which demonstrates that the substrate concentration in
the inhibition studies (100 lM) was below the CMC.
2.3. Enzyme kinetic studies for human 5-lipoxygenase
A steady-state enzyme kinetic analysis of h-5-LOX in the pres-
ence of the activator 23a was performed in order to unravel the
activation mechanism. The kinetic characterization of h-5-LOX
activity versus linoleic acid in the presence of activator 23a shows
a concentration dependent activation (Fig. 3). The activation wasdetermined in the presence of various concentrations of the natu-
ral substrate linoleic acid or the h-5-LOX activator ATP. The initial
velocities of h-5-LOX were determined at various concentration of
ATP, various concentrations 23a (0, 12.5 and 25 lM) and a ﬁxed
concentration of linoleic acid (100 lM). The velocities were plotted
in the Michaelis–Menten and the Lineweaver–Burk plot as shown
in Figure 4.
The Michaelis-–Menten data show that activator 23a causes an
increase in Vmax, whereas the Km remains constant (Table 2).
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Figure 5. Steady-state kinetic characterization of the linoleic acid conversion by h-
5-LOX activation by activator 23a. (A) Michaelis–Menten plots and (B) Lineweaver–
Burk plots show the relation of h-5-LOX activity versus linoleic acid concentrations
at three selected concentrations of 23a (j) 0 lM, (d) 12.5 lM, and (N) 25 lM.
Table 3
Enzyme kinetic parameters for activation of h-5-LOX by activator 23a versus linoleic
acid
23a (lM) Kappm (mM) V
app
max (lM/s) R
2
0 0.590 ± 0.080 2.14 ± 0.21 0.999
12.5 0.438 ± 0.020 2.39 ± 0.07 0.999
25 0.383 ± 0.011 2.70 ± 0.05 0.999
Scheme 3. Kinetic model for non-essential activation.
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Figure 4. Steady-state kinetic characterization of the linoleic acid conversion
versus the ATP concentration of h-5-LOX activator 23a. (A) The Michaelis–Menten
plots and (B) the Lineweaver–Burk plots show the relation of h-5-LOX activity
versus the ATP concentration at three selected concentration of 23a (j) 0 lM, (d)
12.5 lM, and (N) 25 lM in the presence of 100 lM linoleic acid substrate.
Table 2
Enzyme kinetic parameter for activation of h-5-LOX by activator 23a versus ATP
23a (lM) Kappm (lM) V
app
max (nM/s) R
2
0 27.9 ± 1.7 230.9 ± 4.2 0.998
12.5 28.3 ± 1.7 386.1 ± 7.3 0.999
25 28.6 ± 2.3 523.6 ± 13.7 0.999
7768 R. Wisastra et al. / Bioorg. Med. Chem. 21 (2013) 7763–7778Lineweaver–Burk analysis provided similar values. The values
demonstrate non-competitive activation of linoleic acid conversion
by h-5-LOX by compound 23a compared to ATP. The fact that bind-
ing of 23a does not inﬂuence the binding constant of ATP to h-5-
LOX indicates that 23a does not compete for binding in the ATP
binding pocket that allosterically regulates h-5-LOX activity. This
indicates the presence of an allosteric binding pocket that is dis-
tinct from the ATP binding pocket and regulates the h-5-LOX en-
zyme activity.
The enzyme kinetics of 23a were further investigated through
the Michaelis–Menten and the Lineweaver–Burk plots (Fig. 5).
The initial velocities of h-5-LOX at different concentration of lino-
leic acid and a ﬁxed concentration of ATP (100 lM), and at several
selected concentrations of 23a (0, 12.5 and 25 lM) were measured.
Activator 23a causes an increase in Vmax and a decrease in Km (Ta-
ble 3), which indicates non-essential mixed type activation. Thisindicates that the activator can bind to the free enzyme (E,
Scheme 3) and also to the substrate bound enzyme (ES, Scheme 3).
In this model binding of the substrate and 23a mutually inﬂuence
each other. According to this model the activation of h-5-LOX by
23a can be described by Eq. 1 (Fig. 7).
The enzyme kinetic parameters were derived as described in
the material and methods using methods from Leskovac.44 The
activator dissociation constant (KA), the change in the afﬁnity of
Table 4
Enzyme kinetic parameter for inhibition of h-5-LOX by inhibitor 23d versus linoleic
acid
23a (lM) Kappm (mM) V
app
max (lM/s) R
2
0 0.624 ± 0.085 2.24 ± 0.23 0.999
25 0.666 ± 0.121 1.84 ± 0.25 0.998
50 0.690 ± 0.101 1.47 ± 0.16 0.999
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Figure 8. Steady-state kinetic characterization of linoleic acid conversion by h-5-
LOX by inhibitor 23d. (A) Michaelis–Menten plots and (B) Lineweaver–Burk plots
show the relation of h-5-LOX activity versus linoleic acid concentration at three
selected concentrations of 23d (j) 0 lM, (d) 25 lM, and (N) 50 lM.
Scheme 4. Kinetic model for mixed type enzyme inhibition.
Figure 6. Re-plot of 1/D slopes and 1/Dy intercept versus concentration of 23a.
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Figure 7. Equation 1 for the enzyme kinetics according to the model in Scheme 2.44
v is the reaction velocity, Vmax is the maximal reaction velocity, [S] is the substrate
concentration and Km is the Michaelis–Menten constant, [A] is the activator
concentration. a and b, respectively, are the parameters to describe the change in
the afﬁnity of substrate binding and the change in the catalytic constant.
R. Wisastra et al. / Bioorg. Med. Chem. 21 (2013) 7763–7778 7769substrate binding (a) and the change in the catalytic constant (b)
were determined by re-plotting the slopes and the y-interceptions
derived from the Lineweaver–Burk plot as a function of activator
23a concentration (Fig. 6)44 The KA value was determined from
the intersection of 1/Dslopes plot and 1/Dy intercept plot. The
intersection of 1/Dy intercept plot with the ordinate is deﬁned as
bVmax/(b  1) from which the b value was derived. Subsequently,
the resulting b value was substituted to the equation bVmax/Km(-
b  a), which is the intersection of 1/Dslopes plot with the ordi-
nate, to acquire the a value.
The analysis shows that a is 0.0438, b is 1.76 and KA is 8.65 lM.
The a value, which indicates the change in substrate binding, gives
about 50-fold afﬁnity enhancement of the substrate binding to the
activator bound enzyme compared to the free enzyme. Compound
23a shows a high potency as an activator of h-5-LOX with the KA
value in the micromolar range. Furthermore, the afﬁnity of 23a
to the substrate bound enzyme is about 50-fold enhanced, which
indicates that activation of h-5-LOX at high substrate concentra-
tions (>10 lM) takes place at low activator 23a concentrations
(<10 lM) (Fig. 3). The catalytic constant for substrate conversion
reaction was enhanced by 1.76-fold in the presence of the activator
23a compared to the normal reaction conditions. In conclusion,
compound 23a gives a non-essential mixed-type activation of h-
5-LOX and binds with high afﬁnity (aKA = 390 nM) to the substrate
bound enzyme and enhances the conversion of the substrate lino-
leic acid.
The observed results from the enzyme kinetic studies that give
non-essential mixed-type activation versus linoleic acid and non-
essential non-competitive activation versus ATP demonstrate that
there is an allosteric regulatory site in h-5-LOX that is distinct from
the ATP binding site. In order to get a better understanding of this
allosteric site in the regulation of the enzyme activity, we also
studied the inhibition mechanism of h-5-LOX by compound 23d.
Interestingly, compound 23d has a structure that is closely re-
lated to 23a and this compound inhibits h-5-LOX at 50 lM. We
analyzed the underlying enzyme kinetic parameters. The Michae-
lis–Menten plots and the Lineweaver–Burk plots show an increaseof the Kappm and reduction of the K
app
max (Table 4), which is a mixed-
type inhibition of h-5-LOX (Fig. 8). This indicates that inhibitor
23d can bind to the free enzyme as well as to the substrate bound
enzyme following the inhibition model in Scheme 4 from which
the kinetic parameters Vmax and Km can be derived by non-linear
curve ﬁtting of equation 2 (Fig. 9). Furthermore, the changes in
the Km and Vmax are a/a0. Km and Vmax/a0 are used to determine
the Ki and K
0
i values for inhibitor 23d using equations 3 and 4
(Fig. 9). Ki and K
0
i values for inhibitor 23d respectively are
Figure 10. Residual enzyme activity that was observed for compounds 23a and 23d
for inhibition of h-5-LOX in the presence of 50 lM of the respective compounds
with linoleic acid or arachidonic acid as a substrate both at ﬁnal concentrations of
100 lM. The results presented were the average of three independent experiments
and the standard deviations are shown.
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Figure 9. Equations 2(a), 3(b) and 4(c) for the enzyme kinetics according to the
model in Scheme 2. v is the reaction velocity, Vmax is the maximal reaction velocity,
[S] is the substrate concentration and Km is the Michaelis–Menten constant. a and
a0 , respectively, are the parameters to describe the change of substrate binding
afﬁnity to the enzyme and the change of the maximum velocities. Ki is the
dissociation constant of the inhibitor to the free enzyme and K 0i is the dissociation
constant of the inhibitor to the enzyme-substrate complex.
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type inhibition also indicates the presence of an allosteric site in
human 5-lipoxygenase. We presume that compound 23d binds
to the same allosteric binding pocket as 23a but that the difference
in the alkyl chain causes a difference in afﬁnity as well as a change
from activation to inhibition.
Taking this together, the kinetic studies on activation or inhibi-
tion of human 5-lipoxygenase by either 23a or 23d indicate the
presence of an allosteric binding site that inﬂuences the enzyme
activity. In addition, both activation and inhibition obey a compa-
rable kinetic model, which suggests that both effects originate
from the same binding site in the enzyme. Presumably, depending
on the structure of the compounds that bind to this allosteric site
the enzyme would either be activated or inhibited. This is in line
with the literature where the presence of an allosteric binding site
in h-5-LOX that regulates its activity has been described fre-
quently.45–48 We conclude that anacardic acid derivatives can be
used as tools to modulate the h-5-LOX activity toward linoleic acid
and that these compounds modulate the activity of this enzyme by
binding to an allosteric binding site.
We continued our studies with investigation of the modulation
of 23a and 23d of the h-5-LOX activity for arachidonic acid
(Fig. 10). Interestingly, no modulation of the h-5-LOX activity to-
ward arachidonic acid was observed in presence of 23a or 23d.
These results demonstrate that 23a and 23d are selective modula-
tors of linoleic acid conversion and not arachidonic acid conversion
by h-5-LOX.
2.4. Molecular modeling
These results justify the hypothesis that the allosteric regulators
23a and 23d bind to an allosteric regulatory site in h-5-LOX that isclose to the active site. The hypothesis is supported by a previous
report, which stated that h-5-LOX has a wide active site compared
to the others LOXs, which could harbor two substrate molecules.49
The observation that 23a and 23d modulate the conversion of lin-
oleic acid, which has 18 carbon atoms, and not arachidonic acid,
which has 20 carbon atoms, is in line with this hypothesis, because
it is an indication for steric interactions between the substrate and
23a or 23d. Therefore, we hypothesize that the substrates together
with either 23a or 23d bind in the active site, thus resulting in a
different binding constant and a different turnover rate of the sub-
strate linoleic acid. We employed this presumption as a basis for
the modeling studies.
The binding models of the activator 23a and the inhibitor 23d in
the linoleic acid bound as well as the arachidonic acid bound h-5-
LOX active site were made based on the recently published crystal
structure of h-5-LOX (PDB code 3V99).50 The model of h-5-LOX
was further reﬁned using the related PDB structures 3V98 and
3V92 to model Ile673 and its carboxylic acid of the C-terminal
(missing in 3V99), which coordinates the catalytic iron in the ac-
tive site. We note that the model is not meant to capture the role
of the phosphomimic S663D, but only as the structural basis for
substrate binding. Additionally, the active site is in an open conﬁg-
uration accessible to a second small molecule. The above notwith-
standing the structure is nearly indistinguishable from the wild
type structure.50
The arachidonic acid substrate molecule lacks visible speciﬁc
interactions with the protein except for the interaction of the cis
double bond at carbon 11 to the catalytic iron. This lack of visible
speciﬁc interactions renders the virtual re-docking of arachidonic
acid and de novo docking of linoleic acid in the h-5-LOX enzyme
active site futile. Therefore, we modeled a bound structure of lino-
leic acid by manually threading the lipid into the crystal structure
of arachidonic acid using PYMOL.51 The threaded linoleic acid was
then minimized using default settings in UCSF Chimera (version
1.6)52 to produce the ﬁnal model of linoleic acid bound to the h-
5-LOX active site as shown in Figure 11A. This model is justiﬁed
by the high similarity of linoleic acid to arachidonic acid, which
is present in the crystal structure. This model demonstrates that
arachidonic acid protrudes further into the active site then linoleic
acid, which support the idea that steric interaction between 23a
and 23d with the lipid substrate plays a role in the observed en-
zyme kinetics.
Compound 23a and 23dwere docked in the free enzyme, which
can be justiﬁed by the observations that their afﬁnity for the en-
zyme is higher (23a KA 8.6 lM, 23d Ki 70 lM) than the substrate
linoleic acid (Km 600 lM). Using the structure of h-5-LOX with
the arachidonic acid substrate removed, we modeled the binding
mode of 23a and 23d by molecular docking using smina55 and
the resulting poses were reranked using the vina scoring function.
Despite the large binding site (relative to the size of the com-
pound), we observe a common binding mode for compounds 23a
and 23d (as well as 23b and 23c, not shown). Subsequently, the
substrate linoleic acid or arachidonic acid were put into the en-
zyme as described above. This binding mode of 23a and 23d is
characterized by a strong pi–pi stacking interaction between the
central phenyl ring of the compound and Phe177 on one side and
the hydrophobic side chain of Ala410 on the other (Fig. 11B). The
buried polar functionalities of the planar salicylate head group
may be stabilized by a hydrogen bond between the carboxylic –
OH group of the head group and the side chain of His372. Also of
importance is the hydrogen bond between the backbone nitrogen
of Phe177 and the ether oxygen of the hydrophobic tail
(Fig. 11C). The dominant docking poses of compounds 23a–d share
a similar geometry. A few of the low score poses have the salicylate
head group rotated by 180 degrees. Compounds 23a–d are identi-
cal except for the length of their alkoxy tails (Table 1). The only
Figure 11. Docking models of Compounds 23 a,b,c,d in a model of linoleic acid bound to h-5-LOX. (A) Model of bound linoleic acid (yellow) based on a superposition to the
conﬁguration of arachidonic acid in the crystal structure (blue). Front (B) and back (C) view of the highest ranking binding mode of compound 23a (green) and compound 23d
(orange) in the linoleic acid bound active site (A). Yellow dashed lines indicate the hydrogen bond between the ether oxygen and the backbone nitrogen of Phe177. Black
dashed lines indicate hydrophobic interactions. (D) Superposition of highest ranked docked conﬁgurations of compounds 23a (green), 23b (purple), 23c (dark blue), 23d
(orange) show that larger carbon tails block larger portions of the entrance to the catalytic site. Linoleic acid (yellow) and arachidonic acid (blue) are also shown as references.
R. Wisastra et al. / Bioorg. Med. Chem. 21 (2013) 7763–7778 7771differences in the full series of docked conformations is in the long
ﬂexible alkoxy tails of 23c–d that can ﬁt in a variety of conforma-
tions with almost identical energy scores (Fig. 11D).
The models of 23a–d (Fig. 11D) are consistent with our experi-
mental observations. Figure 1 and Table 1 demonstrate that the h-
5-LOX enzymatic activity decreases with an increase in the alkoxy
tail length. In addition, it was observed that 23a and 23d inﬂuence
the linoleic acid conversion and not the arachidonic acid conver-
sion by h-5-LOX (Fig. 10).
Our docking experiments suggest that 23a binds alongside the
substrate linoleic acid and stabilizes its binding and enhances the
enzyme activity. Compound 23d has a longer tail with multiple
binding modes that are likely to block the end of the binding site,
hindering the entry of linoleic acid and thus reducing enzymatic
activity (Fig. 11C). Thus, the shorter linoleic acid substrate leaves
space for the alkoxy tails of 23a and 23d (Fig. 11C). This model
would explain the high afﬁnity of 23a for the linoleic acid bound
enzyme (aKA 0.38 lM) compared to the free enzyme (KA 8.7 lM)
and it is also in line with a higher conversion rate (b 1.76). Perhaps
more interestingly, the model of 23d indicates that an increase in
‘bulk’ for the alkoxy tail provides inhibition of the enzyme activity
for linoleic acid in contrast to the observed activation by 23a.
Namely, the increased ‘bulk’ in 23d must interfere with theenzymatic activity for linoleic acid by disrupting the necessary
binding pose or by blocking the entrance to the active site, which
limits the access of linoleic acid. Conversely, the larger arachidonic
acid might not permit binding of 23a or 23d and thus is its enzy-
matic activity is unaffected.
Taking all these data together we propose a model to explain
our observations. We conclude that compound 23a is an activator
for linoleic acid conversion by h-5-LOX, presumably because it sta-
bilizes the substrate–enzyme complex without blocking the en-
trance to the active site. On the other hand, compound 23d could
bind in a comparable conﬁguration but its larger carbon tail, pre-
sumably, blocks one end of the active site which interferes with
the diffusion of the substrate and molecular oxygen thus overrid-
ing the stabilization effect. Although these models provide plausi-
ble explanations for the observed behavior of this compound class,
we realize crystallography studies would provide the ultimate
experimental proof for the mode of action of these molecules.
3. Conclusion
Anacardic acid derivatives show interesting structure–activity
relationships that demonstrate that these compounds can either
activate or inhibit the activity of human-5-LOX. Compound 23a
7772 R. Wisastra et al. / Bioorg. Med. Chem. 21 (2013) 7763–7778and 23d either activate or inhibit the activity of human 5-LOX to-
ward linoleic acid as a substrate depending on the substitution in
para-position of the 2-(benzyloxy)-6-hydroxybenzoic acid core.
Compound 23a was identiﬁed as a non-essential activator of hu-
man 5-lipoxygenase with KA is 8.65 lM, a is 0.0438, and b is
1.76. The afﬁnity of activator 23a to the substrate bound enzyme
(aKA) is 0.38 lM, which is 50 times higher than to the free enzyme.
Furthermore, activator 23a acts as non-competitive activator
against ATP, which indicates the presence of an allosteric site that
is different from the ATP binding site. Kinetic studies on inhibitor
23d show a mixed type inhibition, which indicates the presence
of an allosteric regulatory site for human 5-LOX activity. Both mod-
ulators 23a and 23d demonstrated no effect on the conversion of
the substrate arachidonic acid by h-5-LOX. Molecular modeling
studies indicate that 23a and 23d bind close to the substrate lino-
leic acid in the active site of h-5-LOX, but that these modulators do
not ﬁt simultaneously in the active site with the arachidonic acid,
which is slightly larger than linoleic acid.
4. Experimental
4.1. Chemistry
4.1.1. General
All reagents and solvents were purchased from commercial
suppliers (Fluka, Sigma–Aldrich, Acros Organics) and were used
without further puriﬁcation. Dichloromethane was distilled over
CaH2 before use. Merck silica gel 60 F254 plates were used for
analytical thin layer chromatography (TLC) and spots were de-
tected by UV light, or stained using KMnO4 solution. Column
chromatography was performed with MP Ecochrom silica gel
32–63, 60 Å using the ﬂash chromatography technique. 1H
(200 MHz) and 13C (50 MHz) NMR spectra were recorded on a
Varian Gemini 200 spectrometer. 13C NMR spectra were recorded
using the attached proton test (APT). Chemical shifts are re-
ported in ppm (d) relative to the solvent. Atmospheric Pressure
Photoionization mass spectra (APPI-MS) and electrospray ioniza-
tion (ESI) were recorded on an Applied Biosystems/SCIEX
API3000-triple quadrupole mass spectrometer. High-resolution
mass spectra (HR-MS) were recorded using a ﬂow injection
method on a LTQ-Orbitrap XL mass spectrometer (Thermo Elec-
tron, Bremen, Germany) with a resolution of 60,000 at m/z 400.
Protonated testosterone (lock mass m/z = 289.2162) was used for
internal recalibration in real time.
N,N,N0,N0-Tetramethyl-p-phenylenediamine (TMPD) hydrochlo-
ride, human 5-lipoxygenase enzyme, and COX-2 (human recombi-
nant) were obtained from Cayman Chemicals. Adenosine tri-
phosphate (ATP), arachidonic acid, and linoleic acid were obtained
from Sigma–Aldrich. Raw Blue cells assay was obtained from Inviv-
oGen. The MTS assay kit was obtained from Promega. Interferon c
(IFN-c) was obtained from PeproTech.
4.1.2. Synthetic procedure 1: synthesis of alkoxy benzyl alcohol
1-Bromo alkane (13 mmol) was added to a light yellow suspen-
sion of hydroxybenzaldehyde (1.1 g, 9.0 mmol) and K2CO3 (5.2 g,
37 mmol) in 45 mL DMF under nitrogen atmosphere. The suspen-
sion was stirred overnight at room temperature. The reaction mix-
ture was diluted with demiwater (100 mL) and extracted with
ethylacetate (3  80 mL). The combined organic layers were
washed with demiwater (4  80 mL), 0.1 M aqueous HCl
(100 mL), brine (2  30 mL), dried with MgSO4, ﬁltered and con-
centrated in vacuo.
NaBH4 (0.17 g, 4.5 mmol) was added to a solution of benzalde-
hyde (8.0 mmol) in 30 mL methanol at 0 C under nitrogen atmo-
sphere. The reaction mixture was stirred for 1 h at 0 C and thenwarmed to room temperature. The reaction mixture was diluted
with demiwater (80 mL) and extracted with ethylacetate
(2  60 mL). The combined organic layers were washed with demi-
water (2  40 mL), brine (2  40 mL), dried with MgSO4, ﬁltered
and concentrated in vacuo. The product was obtained after crystal-
lization or puriﬁcation using column chromatography.
4.1.3. Synthetic procedure 2: bromination of alkyloxy benzyl
alcohol
Phosphorus tribromide (PBr3) (0.34 mL, 3.6 mmol) was added
slowly to a suspension of alkyloxy benzyl alcohol (2.5 mmol) in
10 mL CH2Cl2 under nitrogen atmosphere at 0 C to give an orange
suspension. The reaction mixture was stirred for 1.5 h at 0 C. The
reaction mixture was poured into 80 mL ice water, and extracted
with ethylacetate (3  50 mL). The combined organic layers were
washed with demiwater (50 mL), 0.1 M aqueous HCl (2  30 mL),
brine (50 mL), dried with MgSO4, ﬁltered and concentrated in va-
cuo. The aryl bromide product was obtained after puriﬁcation
using column chromatography.
4.1.4. Synthetic procedure 3: Williamson ether synthesis
coupling of aryl bromide
5-Hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 1
(0.22 g, 1.1 mmol) and K2CO3 (0.63 g, 4.6 mmol) were suspended
in 8 mL DMF under nitrogen atmosphere. A suspension of aryl bro-
mide in 7 mL DMF was added to the suspension. The mixture was
stirred overnight at room temperature and was diluted with demi-
water (60 mL) and extracted with ethylacetate (3  45 mL). The
combined organic layers were washed with demiwater
(2  40 mL), 0.1 M aqueous HCl (40 mL), brine (2  20 mL), dried
over MgSO4, ﬁltered and concentrated in vacuo. The product was
obtained after puriﬁcation using column chromatography.
4.1.5. Synthetic procedure 4: saponiﬁcation of the acetonide
5 M KOH (0.16 mL, 0.80 mmol) was added to a solution of 2,2-
dimethyl-5-((4-(alkyloxy)benzyl)oxy)-4H-benzo[d][1,3]dioxin-4-
one (0.15 g, 0.40 mmol) in 10 mL THF. The reaction mixture was
heated till 60 C and stirred overnight affording an orange suspen-
sion. The reaction mixture was concentrated in vacuo yielding the
product as potassium salt.
4.1.6. Synthetic procedure 5: hydrolysis of acetonide
5 M KOH (1.2 mL, 6 mmol) was added to a colorless solution of
acetonide (0.60 mmol) in 10 mL THF. The reaction mixture was
stirred for 24 h at 62 C. The reaction mixture was diluted and acid-
iﬁed with 1 N aqueous HCl (2.6 mL) and extracted with ethylace-
tate (2  40 mL). The combined organic layers were washed with
water (50 mL), brine (2  30 mL), dried over MgSO4, ﬁltered and
concentrated in vacuo.
4.1.7. (4-(Pentyloxy)phenyl)methanol (2a)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromopentane, and 4-hydroxy-
benzaldehyde using synthetic procedure 1. The product was
puriﬁed using column chromatography with heptane/EtOAc 5:1
(v/v) as an eluent. Yield 73%. Light orange solid. Rf = 0.41 (hep-
tane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.40–7.18 (m, 2H),
6.97–6.79 (m, 2H), 4.59 (s, 2H), 3.95 (t, J = 6.6, 2H), 1.87 (s, 1H),
1.86–1.72 (m, 2H), 1.46–1.34 (m, 4H), 0.94 (t, J = 7.0, 3H). 13C
NMR (50 MHz, CDCl3) d 158.47, 133.10, 128.80, 114.73, 68.24,
65.20, 29.14, 28.38, 22.65, 14.20. MS (APPI): m/z 194.2 [M+].
4.1.8. 1-(Bromomethyl)-4-(pentyloxy)benzene (3a)
The product was obtained from (4-(pentyloxy)phenyl)methanol
2a using synthetic procedure 2. The product was obtained in high
purity and no further puriﬁcation was required. Yield 97%. Yellow
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7.38–7.22 (m, 2H), 6.94–6.74 (m, 2H), 4.51 (s, 2H), 3.94 (t, J = 6.2,
2H), 1.91–1.65 (m, 2H), 1.59–1.21 (m, 4H), 0.94 (t, J = 7.1, 3H).
13C NMR (50 MHz, CDCl3) d 159.47, 130.60, 129.88, 114.94, 68.26,
34.30, 29.11, 28.38, 22.65, 14.22. MS (ESI): m/z 177.1 [MBr]+.
4.1.9. 2,2-Dimethyl-5-((4-(pentyloxy)benzyl)oxy)-4H-
benzo[d][1,3]dioxin-4-one (12a)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-4-(pentyl-
oxy)benzene 3a using synthetic procedure 3. The product was
crystallized from iso-propanol. Yield 70%. White solid. Rf = 0.6
(heptane/EtOAc 1:1).1H NMR (200 MHz, CDCl3) d 7.50–7.32 (m,
3H), 6.90 (d, J = 8.3, 2H), 6.65 (d, J = 8.5, 1H), 6.54 (d, J = 8.2, 1H),
5.18 (s, 2H), 3.95 (t, J = 6.6, 2H), 1.81–1.70 (m, 8H), 1.46 - 1.40
(m, 4H), 0.93 (t, J = 7.1, 3H). 13C NMR (50 MHz, CDCl3) d 160.69,
159.10, 157.99, 136.40, 128.53, 128.26, 114.82, 109.57, 107.62,
105.41, 105.22, 104.17, 70.89, 68.23, 29.17, 28.41, 25.86, 22.67,
14.23. MS (APPI): m/z 370.2 [M+].
4.1.10. Potassium 2-hydroxy-6-((4-
(pentyloxy)benzyl)oxy)benzoate (23a)
The product was obtained from 2,2-dimethyl-5-((4-(pentyl-
oxy)benzyl)oxy)-4H-benzo[d][1,3]dioxin-4-one 12a using syn-
thetic procedure 4. Yield quantitatively determined from the ﬁnal
yield of product in excess of KOH. Orange gum. Rf = 0.16 (hep-
tane/EtOAc 1:1 containing 1% acetic acid). The product was more
than 95% pure as judged from TLC and NMR. 1H NMR (200 MHz,
D2O) d 7.15 (d, J = 8.5, 2H), 6.89 (t, J = 8.3, 1H), 6.68 (d, J = 8.5,
2H), 6.34 (d, J = 8.3, 1H), 6.27 (d, J = 8.3, 1H), 4.91 (s, 2H), 3.68 (t,
J = 6.5, 2H), 1.50–1.47 (m, 2H), 1.14–1.11 (m, 4H), 0.70 (t, J = 7.0,
3H).13C NMR (50 MHz, D2O) d 195.90, 159.11, 158.08, 157.85,
131.54, 129.50, 128.81, 114.48, 111.31, 109.15, 105.52, 70.26,
68.25, 28.21, 27.56, 21.89, 13.38. HRMS: m/z [MH] calcd for
C19H21O5 329.13945, found 329.13995.
4.1.11. (4-(Heptyloxy)phenyl)methanol (2b)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromoheptane, and 4-hydroxy-
benzaldehyde using synthetic procedure 1. The product was
crystallized from heptane. Yield 87%. Colorless to white crystal.
Rf = 0.44 (heptane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.49–
7.16 (m, 2H), 6.99–6.79 (m, 2H), 4.59 (s, 2H), 3.95 (t, J = 6.6, 2H),
1.83 (s, 1H), 1.81–1.71 (m, 2H), 1.55–1.19 (m, 8H), 0.89 (t, J = 6.4,
3H).13C NMR (50 MHz, CDCl3) d 158.97, 133.09, 128.81, 114.75,
68.27, 65.22, 31.98, 29.46, 29.26, 26.20, 22.80, 14.28. MS (APPI):
m/z 222.2 [M+].
4.1.12. 1-(Bromomethyl)-4-(heptyloxy)benzene (3b)
The product was obtained from (4-(heptyloxy)phenyl)methanol
2b using synthetic procedure 2. The product was obtained in high
purity and no further puriﬁcation was required. Yield 97%. Yellow
oil. Rf = 0.71 (heptane/EtOAc 1:1).1H NMR (200 MHz, CDCl3) d
7.37–7.27 (m, 2H), 6.91–6.75 (m, 2H), 4.51 (s, 2H), 3.95 (t, J = 6.5,
2H), 1.91–1.68 (m, 2H), 1.57–1.18 (m, 8H), 0.91 (t, J = 6.5, 3H).13C
NMR (50 MHz, CDCl3) d 159.47, 130.60, 129.87, 114.94, 68.27,
34.30, 31.98, 29.42, 29.25, 26.19, 22.81, 14.29. MS (ESI): m/z
205.1 [MBr]+.
4.1.13. 5-((4-(Heptyloxy)benzyl)oxy)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (12b)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-4-(heptyl-
oxy)benzene 3b using synthetic procedure 3. The product was
puriﬁed using column chromatography with heptane/EtOAc 11:1
(v/v) as an eluent. Yield 78%. White solid. Rf = 0.41 (heptane/EtOAc3:1).1H NMR (200 MHz, CDCl3) d 7.50–7.32 (m, 3H), 6.90 (d, J = 8.6,
2H), 6.90 (d, J = 8.4, 1H), 6.65 (d, J = 8.4, 1H), 5.18 (s, 2H), 3.94 (t,
J = 6.5, 2H), 1.85–1.65 (m, 8H), 1.40–1.30 (m, 8H), 0.89 (t, J = 6.6,
3H). 13C NMR (50 MHz, CDCl3) d 160.68, 159.11, 158.23, 157.99,
136.40, 128.53, 128.25, 114.82, 109.57, 107.61, 105.41, 104.17,
70.88, 68.25, 31.99, 29.48, 29.27, 26.21, 25.85, 22.82, 14.29. MS
(APPI): m/z 398.2 [M+].
4.1.14. Potassium 2-((4-(heptyloxy)benzyl)oxy)-6-
hydroxybenzoate (23b)
The product was obtained from 5-((4-(heptyloxy)benzyl)oxy)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 12b using synthetic
procedure 4. Yield quantitatively determined from the ﬁnal yield
of product in excess of KOH. Orange solid. Rf = 0.49 (heptane/EtOAc
2:1 containing 1% acetic acid). The product was more than 95%
pure as judged from TLC and NMR. 1H NMR (200 MHz, D2O) d
6.93 (m, 2H), 6.60 (m, 1H), 6.42 (m, 2H), 6.18 (m, 1H), 5.94 (m,
1H), 4.74 (s, 2H), 3.38 (m, 2H), 1.31–1.06 (m, 10H), 0.68 (t,
J = 6.6, 3H). 13C NMR (50 MHz, CD3OD) d 202.2, 179.61, 161.89,
161.16, 160.88, 133.19, 131.99, 130.65, 116.15, 111.26, 106.62,
105.29, 72.48, 69.85, 33.85, 31.30, 31.08, 28.01, 24.53, 15.27.
HRMS: m/z [MH]calcd for C21H25O5357.17075, found
357.17109.
4.1.15. (4-(Nonyloxy)phenyl)methanol (2c)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromononane, and 4-hydroxy-
benzaldehyde using synthetic procedure 1. The product was
crystallized from heptane. Yield 73%. White crystal. Rf = 0.44 (hep-
tane:ethylacetate 1:1).1H NMR (200 MHz, CDCl3) d 7.35–7.20 (m,
2H), 6.95–6.82 (m, 2H), 4.60 (s, 2H), 3.95 (t, J = 6.6, 2H), 1.85–
1.74 (m, 2H), 1.71 (s, 1H), 1.42–1.29 (m, 12H), 0.89 (t, J = 7.0,
3H).13C NMR (50 MHz, CDCl3) d 158.99, 133.09, 128.82, 114.76,
68.28, 65.27, 32.08, 29.74, 29.61, 29.47, 26.24, 22.87, 14.31. MS
(APPI): m/z 250.2 [M+].
4.1.16. 1-(Bromomethyl)-4-(nonyloxy)benzene (3c)
The product was obtained from (4-(nonyloxy)phenyl)methanol
2c using synthetic procedure 2. The product was obtained in high
purity and no further puriﬁcation was required. Yield 94%. Light
yellow oil. Rf = 0.74 (heptane/EtOAc 1:1).1H NMR (200 MHz, CDCl3)
d 7.39–7.20 (m, 2H), 6.94–6.76 (m, 2H), 4.50 (s, 2H), 3.95 (t, J = 6.5,
2H), 1.88–1.66 (m, 2H), 1.54–1.14 (m, 12H), 0.89 (t, J = 6.4, 3H).13C
NMR (50 MHz, CDCl3) d 159.48, 130.61, 129.88, 114.96, 68.29,
34.31, 32.09, 29.74, 29.59, 29.47, 29.42, 26.23, 22.88, 14.32. MS
(ESI): m/z 233.1 [MBr]+.
4.1.17. 2,2-Dimethyl-5-((4-(nonyloxy)benzyl)oxy)-4H-
benzo[d][1,3]dioxin-4-one (12c)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-4-(nonyl-
oxy)benzene 3c using synthetic procedure 3. The product was puri-
ﬁed using column chromatography with heptane/EtOAc 15:1 (v/v)
as an eluent. Yield 85%. White solid. Rf = 0.48 (heptane/EtOAc 3:1).
1H NMR (200 MHz, CDCl3) d 7.53–7.29 (m, 3H), 6.90 (d, J = 8.4, 2H),
6.65 (d, J = 8.4, 1H), 6.54 (d, J = 8.4, 1H), 5.18 (s, 2H), 3.94 (t, J = 6.5,
2H), 1.88–1.64 (m, 8H), 1.36 (d, J = 30.5, 12H), 0.88 (t, J = 6.2,
3H).13C NMR (50 MHz, CDCl3) d 202.3, 160.67, 159.09, 158.20,
157.98, 136.39, 128.52, 128.24, 114.81, 109.56, 107.60, 105.40,
102.26, 70.87, 68.24, 32.08, 29.74, 29.61, 29.47, 26.25, 25.85,
22.87, 14.35, 14.31. MS (APPI): m/z 426.2 [M+].
4.1.18. Potassium 2-hydroxy-6-((4-
(nonyloxy)benzyl)oxy)benzoate (23c)
The product was obtained from 2,2-dimethyl-5-((4-(nonyl-
oxy)benzyl)oxy)-4H-benzo[d][1,3]dioxin-4-one 12c using syn-
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yield of product in excess of KOH. Rf = 0.18 (heptane/EtOAc 1:1
containing 1% acetic acid). The product was more than 95% pure
as judged from TLC and NMR. 1H NMR (200 MHz, D2O) d 6.95 (d,
J = 8.3, 2H), 6.57 (t, J = 8.5, 1H), 6.43 (d, J = 8.3, 2H), 6.16 (d,
J = 8.5, 1H), 5.91 (d, J = 8.5, 1H), 4.75 (s, 2H), 3.38 (m, 2H), 1.34
(m, 2H), 1.06 (m, 12H), 0.71 (t, J = 7.0, 3H).13C NMR (50 MHz, CD3-
OD) d 202.2, 164.24, 160.76, 156.88, 133.10, 131.98, 130.67,
116.19, 111.48, 109.33, 106.36, 72.41, 69.89, 61.77, 33.83, 31.47,
31.31, 31.18, 28.10, 27.95, 24.52, 14.22. HRMS: m/z [MH] calcd
for C23H29O5 385.20205, found 385.20248.
4.1.19. (4-((3,7-Dimethyloctyl)oxy)phenyl)methanol (2d)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-1-bromo-3,7-dimethyloctane,
and 4-hydroxybenzaldehyde using synthetic procedure 1. The
product was used for the next reaction step without further puriﬁ-
cation. Yield 92%. Yellow oil. Rf = 0.48 (heptane/EtOAc 1:1). 1H
NMR (200 MHz, CDCl3) d 7.27 (d, J = 8.6, 2H), 6.88 (d, J = 8.6, 2H),
4.59 (s, 2H), 3.98 (t, J = 6.5, 2H), 1.88–1.46 (m, 5H), 1.32–1.14 (m,
6H), 0.93 (d, J = 6.2, 3H),0.87 (d, J = 6.5, 6H).13C NMR (50 MHz,
CDCl3) d 158.98, 133.10, 128.82, 114.77, 66.59, 65.27, 39.45,
37.49, 36.40, 30.06, 28.17, 24.86, 22.91, 22.81, 19.86. MS (APPI):
m/z 264.1 [M+].
4.1.20. 1-(Bromomethyl)-4-((3,7-dimethyloctyl)oxy)benzene
(3d)
The product was obtained from (4-((3,7-dimethyloc-
tyl)oxy)phenyl)methanol 2d using synthetic procedure 2. The
product was used for the next reaction step without further puriﬁ-
cation. Yield quantitative. Light yellow oil. Rf = 0.75 (heptane/
EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.30 (d, J = 8.6, 2H), 6.85
(d, J = 8.6, 2H), 4.49 (s, 2H), 3.98 (t, J = 6.5, 2H), 1.87–1.46 (m,
4H), 1.32–1.10 (m, 6H), 0.93 (d, J = 6.2, 3H), 0.87 (d, J = 6.4,
6H).13C NMR (50 MHz, CDCl3) d 159.46, 130.60, 129.88, 114.95,
66.59, 39.45, 37.47, 36.35, 34.30, 30.04, 28.18, 24.86, 22.92,
22.82, 19.85. MS (ESI): m/z 247.1 [M–Br]+.
4.1.21. 5-((4-((3,7-Dimethyloctyl)oxy)benzyl)oxy)-2,2-dimethyl-
4H-benzo[d][1,3]dioxin-4-one (12d)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-4-((3,7-dime-
thyloctyl)oxy)benzene 3d using synthetic procedure 3. The product
was puriﬁed using column chromatography with heptane/EtOAc
19:1 (v/v) as eluent. Yield 68%. White solid. Rf = 0.35 (heptane/
EtOAc 4:1). 1H NMR (200 MHz, CDCl3) d 7.46–7.26 (m, 3H), 6.92
(d, J = 8.6, 2H), 6.65 (d, J = 8.5, 1H), 6.54 (d, J = 8.5, 1 H), 5.18 (s,
2H), 3.98 (t, J = 6.5, 2H), 1.84–1.5 (m, 10H), 1.32–1.14 (m, 6H),
0.93 (d, J = 6.2, 3H), 0.87 (d, J = 6.4, 6H).13C NMR (50 MHz, CDCl3)
d 160.69, 159.10, 158.23, 157.99, 136.40, 128.53, 128.25, 114.82,
109.57, 107.61, 105.41, 70.89, 66.56, 39.45, 37.49, 36.40, 30.05,
28.17, 25.85, 24.85, 22.91, 22.81, 19.86. MS (APPI): m/z 440.4 [M+].
4.1.22. Potassium 2-((4-((3,7-dimethyloctyl)oxy)benzyl)oxy)-6-
hydroxybenzoate (23d)
The product was obtained from 5-((4-((3,7-dimethyloc-
tyl)oxy)benzyl)oxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one
12d using synthetic procedure 4. The compound is racemic at its
asymmetric carbon. Yield quantitatively determined from the ﬁnal
yield of product in excess of KOH. Orange solid. Rf = 0.54 (heptane/
EtOAc 1:1 containing 1% acetic acid). The product was more than
95% pure as judged from TLC and NMR. 1H NMR (200 MHz, CD3OD)
d 7.42 (d, J = 8.7, 2H), 7.05 (t, J = 8.2, 1H), 6.95–6.85 (m, 2H), 6.43–
6.38 (m, 2H), 5.03 (s, 2H), 3.99 (t, J = 6.7 2H), 1.92–1.48 (m, 4H),
1.40–1.16 (m, 6H), 0.95 (d, J = 6.2, 3H), 0.89 (d, J = 6.5, 6H).13C
NMR (50 MHz, CD3OD) d 202.3, 164.42, 161.42, 160.86, 132.74,132.06, 130.69, 116.17, 111.76, 105.95, 72.47, 68.11, 41.28, 39.28,
38.27, 31.89, 29.99, 26.67, 23.95, 23.86, 20.90. HRMS: m/z [MH]
calcd for C24H31O5 399.2177, found 399.21844.
4.1.23. (3-(Heptyloxy)phenyl)methanol (4b)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromoheptane, and 3-hydroxy-
benzaldehyde using synthetic procedure 1. The product was used
for the next reaction step without further puriﬁcation. Yield 94%.
Brown solid. Rf = 0.48 (heptane/EtOAc 1:1). 1H NMR (200 MHz,
CDCl3) d 7.26–7.18 (m, 1H), 6.96–6.75 (m, 3H), 4.64 (s, 2H), 3.95
(t, J = 6.5, 2H), 1.88–1.67 (m, 3H), 1.55–1.17 (m, 8H), 0.89 (t,
J = 6.5, 3H).13C NMR (50 MHz, CDCl3) d 159.62, 142.67, 129.74,
119.09, 114.01, 113.09, 68.18, 65.48, 31.99, 29.49, 29.27, 26.22,
22.82, 14.34. MS (APPI): m/z 222.2 [M+].
4.1.24. 1-(Bromomethyl)-3-(heptyloxy)benzene (5b)
The product was obtained from (3-(heptyloxy)phenyl)methanol
4b using synthetic procedure 2. Therefore product was used for the
next reaction step without further puriﬁcation. Yield 86%. Brown
solid. Rf = 0.71 (heptane/EtOAc 1:1). 1H NMR (200 MHz,
CDCl3)7.32–6.27 (m, 4H), 4.76 (s, 2H), 3.92 (t, J = 6.4, 2H), 1.72-
1.65(m, 2H), 1.34–1.15 (m, 8H), 0.89 (t, J = 6.5, 3H).13C NMR
(50 MHz, CDCl3) d 159.41, 129.63, 119.81, 114.36, 105.23, 68.05,
32.65, 32.01, 29.53, 29.36, 26.24, 22.84, 14.31. MS (ESI): m/z
285.0 [M+].
4.1.25. 5-((3-(Heptyloxy)benzyl)oxy)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (13b)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-3-(heptyl-
oxy)benzene 5b using synthetic procedure 3. The product was
puriﬁed using column chromatography with heptane/EtOAc 16:1
(v/v) as eluent. Yield 58%. White solid. Rf = 0.29 (heptane/EtOAc
5:1).1H NMR (200 MHz, CDCl3) d 7.42–7.35 (m, 2H), 7.25 (d,
J = 7.5, 1H), 7.04 (d, J = 7.5, 1H), 6.83 (d, J = 7.9, 1H), 6.70–6.49 (m,
2H), 5.22 (s, 2H), 3.99 (t, J = 6.4, 2H), 1.87–1.68 (m, 2H) 1.56 (s, 6H),
1.42– 1.12 (m, 8H), 0.89 (t, J = 6.5, 3H). 13C NMR (50 MHz, CDCl3) d
160.53, 159.77, 158.23, 158.01, 138.02, 136.48, 129.73, 118.57,
114.61, 112.43, 109.67, 107.36, 105.46, 70.74, 68.19, 32.00, 29.50,
29.29, 26.26, 25.85, 22.82, 14.30. MS (APPI): m/z 399.2 [M+H]+.
4.1.26. 2-((3-(Heptyloxy)benzyl)oxy)-6-hydroxybenzoic acid
(24b)
The product was obtained from 5-((3-(heptyloxy)benzyl)oxy)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 13b using synthetic
procedure 5. Yield quantitative. Yellow oil. Rf = 0.42 (heptane/
EtOAc 1:1 containing 1% acetic acid). The product was more than
95% pure as judged from TLC and NMR. 1H NMR (200 MHz,
DMSO-d6) d 7.26–7.19 (m, 2H), 7.08 (d, J = 7.5, 1H), 7.04 (d,
J = 7.5, 1H), 6.79 (d, J = 8.11H), 6.31 (d, J = 8.2, 2H), 5.04 (s, 2H),
3.95 (t, J = 6.4, 2H), 1.73 - 1.63 (m, 2H), 1.36–1.18 (m, 8H), 0.87
(t, J = 7.0, 3H).13C NMR (50 MHz, DMSO-d6) d 170.28, 164.46,
159.34, 158.66, 139.68, 130.82, 129.05, 118.77, 113.03, 110.05,
109.85, 102.77, 69.61, 67.26, 31.26, 28.75, 28.48, 25.55, 22.07,
13.96. HRMS: m/z [MH]calcd for C21H25O5 357.17075, found
357.17114.
4.1.27. (3-(Nonyloxy)phenyl)methanol (4c)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromoheptane, and 3-hydroxy-
benzaldehyde using synthetic procedure 1. The product was used
for the next reaction step without further puriﬁcation. Yield 89%.
Rf = 0.54 (heptane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.22
(t, J = 7.8, 1H), 6.89 (s, 1H), 6.85–6.72 (m, 2H), 4.59 (s, 2H), 3.92
(t, J = 6.5, 2H), 2.32 (s, 1H), 1.79–1.69 (m, 2H), 1.42–1.28 (m,
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142.67, 129.62, 119.04, 113.88, 113.02, 68.11, 65.25, 32.05, 29.72,
29.58, 29.44, 26.22, 22.84, 14.26. MS (APPI): m/z250.2 [M+].
4.1.28. 1-(Bromomethyl)-3-(nonyloxy)benzene (5c)
The product was obtained from (3-(nonyloxy)phenyl)methanol
4c using synthetic procedure 2. Therefore the product was used for
the next reaction step without further puriﬁcation. Yield 78%. Yel-
low oil. Rf = 0.71 (heptane/EtOAc 1:1).1H NMR (500 MHz, CDCl3) d
7.22 (t, J = 7.8, 1H), 6.96–6.92 (m, 2H), 6.84–6.81 (m, 1H), 4.46 (s,
2H), 3.95 (t, J = 7.0, 2H), 1.87–1.75 (m, 2H), 1.47–1.28 (m, 12H),
0.89 (t, J = 6.8, 3H). 13C NMR (50 MHz, CDCl3) d 159.33, 139.04,
129.73, 121,03, 115.03, 114.67, 68.02, 33.55, 31.86, 29.52, 29.38,
29.24, 26.02, 22.65, 14.09. MS (ESI): m/z 313.0 [M+].
4.1.29. 2,2-Dimethyl-5-((3-(nonyloxy)benzyl)oxy)-4H-
benzo[d][1,3]dioxin-4-one (13c)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-3-(nonyl-
oxy)benzene 5c using synthetic procedure 3. The product was puri-
ﬁed using column chromatography with heptane/EtOAc 16:1 (v/v)
as eluent. Yield 88%. Yellow oil. Rf = 0.29 (heptane/EtOAc 5:1). 1H
NMR (500 MHz, CDCl3) d 7.41–7.35 (m, 2H), 7.25–7.20 (m, 2H),
7.04 (d, J = 7.0, 1H), 6.82 (d, J = 6.9, 1H), 6.59 (d, J = 8.0, 1H), 5.21
(s, 2H), 3.99 (t, J = 6.0, 2H), 1.89–1.62 (m, 8H), 1.51–1.13 (m,
12H), 0.87 (d, J = 6.3, 3H).13C NMR (50 MHz, CDCl3) d 160.46,
159.71, 157.95, 137.97, 136.45, 129.66, 118.51, 114.55, 112.37,
109.62, 107.30, 105.39, 103.97, 70.68, 68.13, 32.04, 29.71, 29.60,
29.43, 26.26, 25.79, 22.83, 14.28. MS (ESI): m/z 427.3 [M+H]+.
4.1.30. 2-Hydroxy-6-((3-(nonyloxy)benzyl)oxy)benzoic acid
(24c)
The product was obtained from 5-((3-(heptyloxy)benzyl)oxy)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 13c using synthetic
procedure 5. The product was obtained in high purity and no fur-
ther puriﬁcation was required. Yield 58%. Yellow oil. Rf = 0.60 (hep-
tane/EtOAc 1:1 containing 1% acetic acid). The product was more
than 95% pure as judged from TLC and NMR. 1H NMR (200 MHz,
CD3OD) d 7.27–7.20 (m, 2H), 7.11–7.01 (m, 2H), 6.81 (d, J = 7.8,
1H), 6.49 (d, J = 7.5, 2H), 5.16 (s, 2H), 3.97 (t, J = 6.2, 2H), 1.75–
1.71 (m, 2H), 1.41–1.23 (m, 12H), 0.90 (t, J = 6.5, 3H).13C NMR
(50 MHz, CD3OD) d 185.96, 161.65, 156.96, 141.16, 131.25,
121.03, 115.76, 115.03, 107.29, 94.05, 72.58, 69.81, 33.92, 31.56,
31.43, 31.30, 28.07, 24.59, 15.30. HRMS: m/z [MH] calcd for
C23H29O5 385.20205, found 385.20261.
4.1.31. 2,2-Dimethyl-5-(nonyloxy)-4H-benzo[d][1,3]dioxin-4-
one (11)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-bromononane using synthetic
procedure 3. The product was puriﬁed using column chromatogra-
phy with heptane as eluent followed by heptane/EtOAc 50:1 (v/v)
as eluent until the starting material was completely removed from
the column and the product was obtained by eluting the column
with EtOAc as eluent. Yield 53%. Light yellow solid. Rf = 0.64 (hep-
tane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.40 (t, J = 8.4, 1H),
6.59 (d, J = 8.1, 1H), 6.51 (d, J = 8.2, 1H) 4.06 (t, J = 6.7, 2H), 1.95–
1.81 (m, 2H), 1.69 (s, 6H), 1.50–1.26 (m, 12H), 0.85 (t, J = 6.6,
3H).13C NMR (50 MHz, CDCl3) d 161.30, 158.20, 157.96, 136.41,
109.03, 106.62, 105.28, 103.67, 69.60, 32.07, 29.69, 29.55, 29.46,
29.14, 26.03, 25.84, 22.86, 14.31. MS (APPI): m/z 321.0 [M+H]+.
4.1.32. 2-Hydroxy-6-(nonyloxy)benzoic acid (22)
The product was obtained from 5-((3-(heptyloxy)benzyl)oxy)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 11 using synthetic
procedure 5. The product was obtained in high purity and nofurther puriﬁcation was required. Yield quantitative. Light brown
solid. Rf = 0.60 (heptane/EtOAc 1:1 containing 1% acetic acid). The
product was more than 95% pure as judged from TLC and NMR.
1H NMR (200 MHz, DMSO-d6) d 7.02 (t, J = 8.2, 1H), 6.28 (d,
J = 8.0, 1H), 6.24 (d, J = 8.1, 1H), 3.87 (t, J = 6.5, 2H), 1.68–1.58 (m,
2H), 1.40–1.17 (m, 12H), 0.86 (t, J = 6.5, 3H).13C NMR (50 MHz,
DMSO-d6) d 164.31, 160.21, 131.19, 110.51, 109.82, 103.07,
69.00, 31.74, 29.48, 29.34, 29.14, 25.92, 22.54, 14.40. HRMS: m/z
[MH] calcd for C16H23O4 279.16018, found 279.16061.
4.1.33. 1-(4-Bromophenyl)decan-1-one (7)
The product was obtained using Friedel–Craft acylation of bro-
mobenzene 6 with decanoylchloride. AlCl3 (0.81 g, 6.1 mmol) was
added slowly to a solution of bromobenzene (0.54 mL, 5.1 mmol)
and decanoylchloride (1.2 mL, 5.8 mmol) in 20 mL CH2Cl2 in a
50 mL ﬂask at 0 C. AlCl3 slowly dissolved in the mixture and the
reaction mixture was stirred for 1 hour at 60 C. The reaction mix-
ture was poured into ice-water (25 mL) and extracted with CH2Cl2
(2  30 mL). The combined organic layers were dried over brine
and concentrated in vacuo. The product was dissolved in CH2Cl2
and washed with 2 N aqueous HCl (2  15 mL) and dried over
brine (15 mL) and concentrated in vacuo. The product was crystal-
lized from heptane in a yield 62% (0.49 mg, 1.5 mmol) as a white
solid. Rf = 0.69 (heptane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d
7.89–7.75 (m, 2H), 7.65–7.53 (m, 2H), 2.92 (t, J = 7.5, 2H), 1.75–
1.64 (m, 2H), 1.32–1.27 (m, 12H), 0.87 (t, J = 6.4, 3H).13C NMR
(50 MHz, CDCl3) d 199.72, 136.01, 132.06, 129.82, 128.19, 38.81,
32.08, 29.67 (2C), 29.54, 29.49, 24.50, 22.88, 14.32. MS (APPI): m/
z 311.2 [M+].
4.1.34. 1-Bromo-4-decylbenzene (8)
The product was obtained using a Wolff–Kishner reaction to re-
duce 1-(4-bromophenyl)decan-1-one 7. 1-(4-Bromophenyl)decan-
1-one 7 (1.3 g, 4.2 mmol), hydrazine monohydrate (1.2 mL,
16 mmol) and KOH (1.8 g, 32 mmol) were dissolved in 25 mL of
1-octanol to yield a green suspension in a two-necked 50 mL ﬂask.
The reaction mixture was stirred at reﬂux at 135 C for 23=4 h to give
an almost colorless solution. The reaction mixture was then cooled
to room temperature and diluted with ether (50 mL), washed with
1 N aqueous HCl (50 mL), 2 N aqueous HCl (20 mL), brine (2 times,
30 mL), dried over MgSO4, ﬁltered, concentrated in vacuo. 1-Octa-
nol was removed by vacuum distillation to yield about 2.7 g of the
crude product. The product was puriﬁed using column chromatog-
raphy with heptane as eluent. Yield 40%. Colorless oil. Rf = 0.61
(100% heptane). 1H NMR (500 MHz, CDCl3) d 7.37 (d, J = 8.3, 2H),
7.03 (d, J = 8.1, 2H), 2.54 (t, J = 7.7, 2H), 1.60–1.54 (m, 2H), 1.28–
1.25 (m, 14H), 0.88 (t, J = 6.8, 3H).13C NMR (50 MHz, CDCl3) d
142.05, 131.46, 130.37, 119.47, 35.59, 32.14, 31.56, 29.85, 29.82,
29.71, 29.57, 29.43, 22.93, 14.34. MS (APPI): m/z 296.2 [M+].
4.1.35. ((4-Decylphenyl)ethynyl)trimethylsilane
Into a dried 10–20 mL microwave vial, PdCl2(PPh3) (52 mg,
74 lmol), CuI (18 mg, 95 lmol), and PPh3 (80 mg, 0.30 mmol) were
suspended in CH3CN (2 mL) under nitrogen atmosphere. Subse-
quently, 1-bromo-4-decylbenzene 8 (0.46 g, 1.5 mmol), diethyl
amine (Et2NH) (2.4 mL, 23 mmol), and trimethylsilyl acetylene
(TMSA) (0.24 mL, 1.7 mmol), were added to the mixture. The mix-
ture was heated at 120 C for 35 min via microwave irradiation
(95 W). The reaction mixture was diluted with EtOAc (50 mL)
and washed with water (3  50 mL). The water layer was washed
with EtOAc (2  50 mL). The combined organic phases were ex-
tracted with brine (1  50 mL) and dried over Mg2SO4. The solvent
was evaporated under reduced pressure and the residue was puri-
ﬁed by column chromatography with heptane as eluent. Yield 65%.
Brown oil. Rf = 0.41 (100% heptane). 1H NMR (500 MHz, CDCl3) d
7.37 (d, J = 8.0, 2H), 7.10 (d, J = 7.9, 2H), 2.58 (t, J = 7.6, 2H), 1.58–
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9H);13C NMR (50 MHz, CDCl3) d 143.89, 132.08, 128.52, 120.44,
105.63, 93.45, 36.11, 32.12, 31.42, 29.82, 29.69 (2C), 29.55, 29.42,
22.91, 14.34, 0.26. MS (APPI): m/z 314.2 [M+].
4.1.36. 1-Decyl-4-ethynylbenzene (9)
((4-Decylphenyl)ethynyl)trimethylsilane (0.29 g, 0.91 mmol)
was dissolved in THF (5 mL) and the solution was cooled to 0 C.
Tetra butyl ammonium ﬂuoride (TBAF) (1.4 mL, 1.4 mmol) in THF
(1 M, 2.6 mL) was added dropwise and the reaction mixture was
stirred for 10 min. The reaction mixture was diluted with EtOAc
(50 mL), extracted with water (4  50 mL) and washed with brine
(2  50 mL). The organic phase was dried over MgSO4 and ﬁltered.
The solvent was evaporated and the product was used without fur-
ther puriﬁcation. Yield 93%. Brown oil. Rf = 0.45 (100% heptane). 1H
NMR (500 MHz, CDCl3) d 7.40 (d, J = 8.0, 2H), 7.13 (d, J = 7.8, 2H),
3.02 (s, 1H), 2.59 (t, J = 7.6, 2H), 1.59–1.55 (m, 2H), 1.29–1.26 (m,
14H), 0.88 (t, J = 6.8, 2H).13C NMR (50 MHz, CDCl3) d 144.22,
132.25, 128.63, 119.41, 105.22, 92.67, 36.12, 32.12, 31.45, 29.82,
29.79, 29.69, 29.55, 29.46, 22.91, 14.34. MS (APPI): m/z 242.2 [M+].
4.1.37. Benzyl 2,4-bis(benzyloxy)-6-((4-
decylphenyl)ethynyl)benzoate
The product was obtained using Sonogashira coupling reaction
of 2,4-bis(benzyloxy)-6-(((triﬂuoromethyl)sulfonyl)oxy)benzoate
10, and 1-decyl-4-ethynylbenzene 9. Distilled diethylamine
(0.11 mL, 1.05 mmol) and 1-decyl-4-ethynylbenzene 9 (0.18 g,
0.74 mmol) were subsequently added to a solution of the triﬂate
10 (0.36 g, 0.63 mmol), CuI (9.0 mg, 47 lmol), and PdCl2(PPh3)2
(18 mg, 0.026 mmol) in degassed anhydrous acetonitrile (1.0 mL)
under nitrogen atmosphere. The mixture was subjected to micro-
wave irradiation for 35 min at 120 C (70 W). The reaction mixture
was diluted with ether (50 mL) and washed with demi water
(2  30 mL), brine (2  50 mL), dried over MgSO4 and ﬁltered.
The solvent was evaporated under reduced pressure, and the resi-
due was puriﬁed by column chromatography with heptanes/EtOAc
5:1 (v/v) as eluent. Yield 80%. Brown oil. Rf = 0.40 (heptane/EtOAc
1:1). 1H NMR (500 MHz, CDCl3) d 7.43–7.27 (m, 15H), 7.22 (d,
J = 8.0, 2H), 7.12 (d, J = 7.9, 2H), 6.75 (s, 1H), 6.56 (s, 1H), 5.37 (s,
2H), 5.06 (s, 2H), 5.04 (s, 2H), 2.60 (t, J = 7.5, 2H), 1.60- 1.55 (m,
2H), 1.30- 1.26 (m, 14H), 0.88 (t, J = 6.6, 3H).13C NMR (50 MHz,
CDCl3) d 166.91, 160.54, 157.24, 144.06, 136.47, 136.38, 136.09,
131.89, 128.89, 128.76, 128.61, 128.48, 128.44, 128.17, 128.12,
127.75, 127.30, 123.86, 120.06, 119.89, 109.67, 101.97, 93.47,
86.28, 70.80, 70.53, 67.30, 36.15, 32.12, 31.47, 29.81, 29.71,
29.55, 29.46, 22.91, 14.34. MS (APPI): m/z 665.2 [M+H+].
4.1.38. 2-(4-Decylphenethyl)-4,6-dihydroxybenzoic acid (20)
Benzyl 2,4-bis(benzyloxy)-6-((4-decylphenyl)ethynyl)benzoate
(0.28 g, 0.42 mmol) was dissolved in EtOAc (due to low solubility
in MeOH) and added to 10 mol% Pd/C (10%) (45 mg, 42 nmol).
The suspension was shaken with 3 atm H2-pressure in a Parr appa-
ratus at 45 C for 24 h. Subsequently, the mixture was ﬁltered
through Celite. The solvent was evaporated under reduced pres-
sure and the residue was puriﬁed by column chromatography with
heptane/EtOAc 9:1 (v/v) as eluent, followed by EtOAc as eluent to
obtain the desired product. Yield 72%. White solid. Rf = 0.40 (hep-
tane/EtOAc 1:1 + acetic acid). The product was more then 95% pure
as judged from TLC and NMR. 1H NMR (200 MHz, CD3OD) d 7.12–
7.02 (m, 4H), 6.18 (d, J = 2.4 Hz, 1H); 6.16 (d, J = 2.4 Hz, 1H),
3.18–3.10 (m, 2H), 2.83–2.75 (m, 2H), 2.62–2.48 (m, 2H), 1.60–
1.50 (m, 2H), 1.28–1.20 (m, 14H), 0.89 (t, J = 6.5, 3H).13C NMR
(50 MHz, CD3OD) d 167.82, 164.57, 150.02, 142.23, 141.60,
130.15, 112.86, 106.44, 102.82, 41.15, 40.02, 37.41, 33.93, 33.67,
31.59, 31.47 (2C), 31.31, 31.19, 24.59, 15.30. HRMS: m/z [MH]
calcd for C25H33O4 397.23843, found 397.2388.4.1.39. 2-(Benzo[d]oxazol-2-yl)phenol (26)
Salicylic acid (0.138 g, 1.0 mmol) was mixed with 2-aminophe-
nol (0.11 g, 1.0 mmol) and 3 mL of polyphosphoric acid was added
to the mixture. The mixture was heated in oil bath at 180 C under
N2 for 6.5 h. The reaction mixture was cooled to room temperature
and subsequently poured into 150 mL demi water. The mixture
was extracted with ethylacetate (2  30 mL). The combined organ-
ic layers were washed with demiwater (2  40 mL), brine
(1  40 mL), dried with MgSO4, ﬁltered and concentrated in vacuo.
The product was obtained after crystallization or puriﬁcation using
column chromatography with heptane/EtOAc 50:1 (v/v) as eluent.
Yield 47%. Colorless to white crystals. Rf = 0.69 (heptane/EtOAc
1:1). The product was more than 95% pure as judged from TLC
and NMR. 1H NMR (200 MHz, DMSO) d 8.04 (dd, J = 7.9, 1.7, 1H),
7.83-7.89 (m, 2H), 7.53–7.58 (m, 1H), 7.45–7.50 (m, 2H), 7.06–
7.16 (m, 2H).13C NMR (50 MHz, DMSO) 158.17, 151.40, 149.24,
139.90, 134.41, 128.04, 126.31, 125.77, 120.43, 119.64, 117.63,
111.50, 110.84. HRMS: m/z [M+H]+ calcd for C13H10O2N1
212.07061, found 212.07051.
4.2. Enzyme activity studies
4.2.1. Human 5-LOX inhibition screening UV assay
Enzyme inhibition was measured by the residual enzyme activ-
ity after 10 min incubation with the inhibitor at room temperature.
The enzyme activity was determined by conversion of lipoxyge-
nase substrate linoleic acid into hydroperoxy-octadecadienoate
(HPOD). The conversion rate was followed by UV absorbance of
the conjugated diene at 234 nm (e = 25000 M1 cm1) over a peri-
od of 20 min. The UV absorbance increase over time was used to
determine the enzyme activity.
Tris buffer (50 mM) pH 7.5 containing 2 mM EDTA and 2 mM
CaCl2 was used as an assay buffer for human 5-LOX experiments.
The human 5-LOX enzyme was diluted 1:4000 with the assay buf-
fer. The inhibitor (100 mM in DMSO) was diluted with the assay
buffer to 1 mM. The substrate, linoleic acid was diluted with EtOH
to 20 mM. Subsequently, 1 mL of enzyme solution (1:4000) was
mixed with 100 lL ATP (2 mM), 100 lL inhibitor (1 mM) and
790 lL Tris buffer and incubated for 10 min. After that the linoleic
acid solution (10 lL, 20 mM) was added to a mixture and the con-
version rate of the substrate was measured after 10 s mixing of the
enzyme with the substrate. The reaction rate in the absence of the
inhibitor was used as positive control. In the positive control
experiment, the assay buffer was supplemented with a small
amount of DMSO (3 lL of DMSO in 1.5 mL) in order to replace
the DMSO inhibitor solution, which was also pre-incubated for
10 min.
4.2.2. COX-2 inhibition screening assay
The COX-2 activity was measured spectrophotometrically by
measuring the formation of oxidized N,N,N0,N0-tetramethyl-p-
phenylenediamine (TMPD). Tris buffer (0.1 M) pH 8.0 was used
as an assay buffer for COX-2 experiments. The COX-2 enzyme
was diluted 1:1000 with the assay buffer. Hematin (7.5 mM in
DMSO) was diluted with assay buffer to 330 lM. The inhibitor
was diluted to 1.1 mM in DMSO. The substrate, arachidonic acid
was diluted by adding 50 lL KOH 0.1 M and 800 lL H2O into
150 lL of a 22 mM arachidonic acid solution in EtOH. The colori-
metric substrate TMPD (2.64 mM in H2O) was prepared freshly
prior to the experiment. The substrate, linoleic acid was diluted
with EtOH to 20 mM. Subsequently, in a 96 wells plate, 150 lL as-
say buffer, 10 lL hematin 330 lM, 10 lL COX-2 enzyme (1:1000)
was added. 10 lL inhibitor solution (1.1 mM in DMSO) was added
to the inhibitor well and 10 lL of DMSO was added to the positive
control wells. The plate was incubated for 5 min at room tempera-
ture. 20 lL of freshly prepared TMPD was added followed by the
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excluded from the negative control wells. The plate was incubated
for another 5 min at room temperature. The absorbance was mea-
sured at 550 nm, and the calculations were performed with Excel
2010. The experiments were performed in triplicate, and the pre-
sented results were the average of three measurements with the
standard deviation.
4.2.3. Michaelis Menten enzyme kinetics
The enzyme kinetics of human 5-LOX were also studied by the
formation of the conjugated diene product at 234 nm
(e = 25000 M1 cm1) using the same experimental setup as for
the concentration dependent and the inhibitor screening. Enzyme
kinetics were performed against linoleic acid and ATP to get a com-
plete indication about the regulation of human 5-LOX enzyme
activity.
In the kinetic study of the human 5-LOX against ATP, the ATP
concentration was varied between 12.5–200 lM while the con-
centration of linoleic acid was ﬁxed (100 lM). In the kinetic
study of the human 5-LOX against the linoleic acid, substrate
concentration was varied between 37.5–300 lM. The enzyme
activity was measured in the absence or presence of ﬁxed con-
centrations of activator 23a (0 lM, 12.5 lM, and 25 lM) or
inhibitor 23d (0 lM, 25 lM, and 50 lM). The reaction velocities
(v), which are the concentration changes over time, were plotted
against the substrate concentrations in Michaelis–Menten plots
and the Km and Vmax and the apparent values (K
app
m and K
app
max)
in the presence of the activator were derived. The results from
the non-linear curve ﬁtting were in line with the results from
Lineweaver–Burk plot.
The slopes and y-intercepts from the Lineweaver–Burk plot of
h-5-LOX activation was derived and then re-plotted as 1/Dslope
or 1/Dy intercept versus 1/[activator]. From these plots a, b and
KA values were derived as described by Leskovac44 for non-essen-
tial activation. According to this method in the re-plot of 1/Dy
intercept versus 1/[activator] the y intercept corresponds to b
(Vmax/(b  1)), whereas in the re-plot of 1/Dslope versus 1/[activa-
tor] the y intercept correspond to bVmax/Km(b  a). The x intersec-
tion point of two lines from the plot of 1/Dy intercept and 1/Dslope
is b/aKA, which can be employed to derive the KA value if a and b
are known. All the experiments were performed in triplicate and
the average triplicate values and their standard deviations are plot-
ted. Calculations were performed with Excel 2010.
4.3. Docking studies
4.3.1. Protein and ligand structures
Structures of compounds 23a, 23b, 23c, and 23d were built
using Omega2 from OpenEye53 We ﬁxed the rotatable bonds be-
tween the benzyl ring and the carboxylic acid group on all mole-
cules using AutoDockTools to dock structures that kept a planar
geometry for the benzyl ring and carboxylic acid.54
4.3.2. Docking and scoring
The receptor structure was prepared for docking using the pre-
pare_receptor4.py script from AutoDockTools. Compounds were
docked using smina55 with the default vina scoring function and
the argument ‘–num_modes = 40’. The docked poses were rescored
using the ‘–score_only’ command in smina and then reranked. The
top ranked poses were used for further analysis.
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